PRP for Alopecia Areata: Can Autologous Plasma Help?

Alopecia areata is an autoimmune condition in which the body's immune system mistakenly targets hair follicles, leading to localised or more widespread hair loss. It typically presents as smooth, coin-shaped patches of hair loss on the scalp, though it can also affect the beard, eyebrows, eyelashes, and body hair.

The condition can be unpredictable in its course. Some individuals experience spontaneous regrowth, while others may have recurring episodes or more extensive loss over time. Any treatment approach should be discussed with a suitably qualified healthcare professional who can assess the nature and severity of the hair loss and explore appropriate management options.

Platelet-rich plasma (PRP) therapy is a procedure that uses a small sample of the patient's own blood to create a concentrated plasma solution rich in platelets and growth factors. Because it is derived from the patient's own biological material, it is described as autologous — meaning the risk of allergic reaction is substantially reduced compared to externally derived substances. Individual reactions remain possible and suitability must be assessed during consultation.

The procedure involves drawing a small volume of blood, processing it in a centrifuge to separate the plasma from red blood cells, and then preparing the platelet-rich fraction for injection. In the context of hair loss, PRP is typically administered through a series of micro-injections into the scalp at the level of the hair follicles.

In alopecia areata, inflammation around the follicle — driven by immune cell activity — disrupts the hair growth cycle and places affected follicles in a prolonged resting or miniaturised state. Crucially, in most cases of alopecia areata, the follicle itself is not permanently destroyed, which is why spontaneous regrowth can occur.

Concentrated growth factors in PRP — including PDGF, VEGF, TGF, and IGF — are thought to promote blood vessel formation around follicles, stimulate dermal papilla cells that regulate hair growth, extend the anagen phase, and potentially modulate localised inflammatory activity.

Several randomised controlled trials and observational studies have reported improvements in hair density, regrowth rates, and patient-reported outcomes following a course of PRP injections in individuals with patchy alopecia areata. Some studies have compared PRP with intralesional corticosteroid injections, with some suggesting comparable or additive benefits.

The quality and scale of available evidence remains limited. Study designs, PRP preparation protocols, and patient populations vary considerably across the literature. There is currently no universal consensus on optimal PRP concentration, injection intervals, or the number of sessions required.

Those who may be considered for assessment include adults with patchy alopecia areata who have explored or are concurrently using other management approaches, individuals with early or moderate hair loss where follicular activity is still present, and patients in good general health without contraindications.

PRP therapy may be less suitable for individuals with active scalp infections, anticoagulant medications or coagulation disorders, severe or total alopecia, pregnancy or breastfeeding, or haematological conditions affecting platelet function. Our broader guide on who may be suitable for PRP hair therapy provides additional suitability context.

Some individuals report visible improvement in hair density and coverage following a course of PRP sessions, typically administered at monthly intervals over three to six months. However, responses vary considerably, influenced by the extent and duration of hair loss, disease activity at the time of treatment, and individual biological variation.

PRP therapy typically requires ongoing maintenance sessions to sustain any observed benefits. Permanent or guaranteed regrowth cannot be promised, and results may not be equivalent across different patients.

PRP is one of several approaches that may be considered in the management of alopecia areata. For those weighing up non-surgical versus surgical routes, our guide on PRP vs hair transplant provides a useful comparison. Other commonly discussed options include intralesional corticosteroid injections (a well-established first-line option), topical immunotherapy, minoxidil, JAK inhibitors (prescription-only medicines requiring specialist medical supervision, which are an emerging class with promising research), and microneedling.

PRP is generally considered an adjunctive rather than a replacement for established dermatological treatments. Patients are encouraged to discuss all available options — and their relative evidence bases — with a suitably qualified healthcare professional.

PRP (platelet-rich plasma) therapy uses the patient's own blood-derived plasma to deliver growth factors to the scalp, with the aim of supporting follicular activity in alopecia areata. The evidence is encouraging but still evolving — outcomes are not guaranteed or universal.

Alopecia areata is an autoimmune condition, and PRP is best considered as an adjunctive approach rather than a standalone cure. Multiple sessions are typically required, with ongoing maintenance often needed to sustain any observed benefits. To discuss your individual circumstances with a GDC or GMC-registered practitioner at our CQC-regulated clinic, book a consultation.